Home : FDA Drug Database : Abraxane : News Articles

Abraxane - News Articles

Arch Dermatol -- Sign In Page: Treatment was begun with weekly paclitaxel for 12 weeks. His left cervical lymphadenopathy resolved in 4 weeks, and his skin lesion disappeared in 3 months. ...
The cancer drug paclitaxel - Investors.com: The cancer drug paclitaxel has been shown to promote regeneration of injured nerve cells, according to scientists in the US and Europe, who say it could treat spinal cord injuries and paralysis. The drug also inhibits the production of scar tissue that can be a ...
Breast Cancer: Top 5 Drugs That Work: Abraxane IV. This drug is used to treat advanced breast cancer. Paclitaxel (Taxol) is a cancer chemotherapy drug that works by slowing or stopping the cancer cell growth. 3. Epirubicin. It slows or stops the growth of cancer cells. 4. Femara oral. This drug ...
Platinum today: Boston Scientific to present platinum chromium stent test results: "Our PROMUS Element Everolimus-Eluting Stent System and TAXUS Element Paclitaxel-Eluting Stent System continue to be well received by European physicians. " The PROMUS Element stent clinical and angiographic outcomes will be presented on 21st September, with the TAXUS Element stent ...
IMP321 Achieves Benefit in MBC Patients: Immutep SA announced the publication of a clinical research paper showing that its lead product, IMP321, given with first-line paclitaxel achieved clinical benefit in 90 per cent of metastatic breast carcinoma (MBC) patients. Correlations were observed with both the patients' monocyte ...
Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2011 Clinical Progress and Financial Results - MarketWatch: These results exceed the 15% ORR and 4.5 month median PFS of carboplatin and paclitaxel alone from a separate historical trial. Cotara(R) Phase II Brain Cancer Trial By year-end, Peregrine expects to complete enrollment in its Phase II safety and ...
Rexahn Pharmaceuticals Announces Publication of New Preclinical Research Data for Novel Anticancer Compound RX-8243 - MarketWatch: "The study clearly demonstrates that RX-8243 inhibited tumor formation in paclitaxel-resistant cancer model, suggesting that isoquinolineamine and its analogues have the potential to become a novel class of anti-tumor chemotherapeutics." About Rexahn Pharmaceuticals, Inc. Rexahn Pharmaceuticals is ...
Bracing for a Double-Dip Recession: Eight Recession-Proof Stocks -- Seeking Alpha: By proxy, that could also benefit Celgene, whose Abraxane is used to treat solid tumor malignancies, such as lung cancer. Disclaimer: Money Morning and Stansberry & Associates Investment Research are separate companies, and entirely distinct. Their only common thread is a shared parent ...
Nanovehicle acts as cluster bomb for tumors: filled with paclitaxel were more effective than either free paclitaxel or Abraxane—an albumin nanoparticle loaded with paclitaxel—at stopping tumor growth. Source: National Cancer Institute addthis_logo = 'http://www.nanowerk.com/images/nwlogo200x50.gif'; addthis_logo_background = 'FFFFFF'; addthis_logo_color = '000066'; addthis_brand = 'Nanowerk'; addthis_options = ...

News - Phased Ipilimumab Plus Paclitaxel/Carboplatin Shows Promise in Treatment of NSCLC: Presented at ASCO: CHICAGO -- June 11, 2010 -- Ipilimumab (IPI) given with paclitaxel/carboplatin (P/C) in a phased manner, extends immune-related progression-free survival (irPFS) in non-small-cell lung cancer (NSCLC) compared with P/C alone, according to a study presented here at ...
News - Novel Paclitaxel Formulation Encouraging for Treating Advanced Lung Cancer: In the multicentre study, researchers sought to determine the optimal dose nab-paclitaxel, which can be administered safely at higher doses than the solvent-based paclitaxel and has performed well when treating patients with breast cancer. A total ...
The Week’s Big Movers | Los Angeles Business Journal: Abraxis BioScience Inc. ended the week up 9.7 percent to $59.75 after the Los Angeles biotech released positive studies on its cancer drug Abraxane at a major oncology meeting in Chicago. American Apparel Inc., which has struggled due to production issues, ended the ...
It’s still difficult to navigate Ontario’s cancer treatment maze - St. Catharines Standard - Ontario, CA: Dragicevic learned a breast cancer drug, Abraxane, is used at the Mayo Clinic in Arizona to reduce pancreatic tumours, but that is an off-label use not funded by OHIP. The mother of an eight-year-old daughter decided to go to Arizona for treatment and ...
Options for Sirolimus-Eluting Stent Restenosis Evaluated - Study shows sirolimus- and paclitaxel-eluting stents can treat in-SES restenosis equally well - ModernMedicine: a repeat SES or a paclitaxel-eluting stent (PES), according to a study published online March 10 in the Journal of the American College of Cardiology. ...
Combination IV paclitaxel, carboplatin showed viability at certain doses for gynecologic cancers | HemOncToday: Intravenous paclitaxel and intraperitoneal carboplatin, and intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel may be viable treatment options for patients with previously untreated ovarian, fallopian tube and primary peritoneal carcinoma, according ...
OTC Tip Reporter: Reports Active Stocks To Watch For April 7, 2010 Are April 6, 2010 - Artfest International, Inc. (OTCBB: ARTS) | TradingMarkets.com: About Tesetaxel Taxanes (including paclitaxel and docetaxel) are the most widely used chemotherapy drug class in cancer medicine. However, these agents are associated with serious safety issues, particularly hypersensitivity reactions related to intravenous infusions that are occasionally fatal and that require ...
Indena´s Myrtocyan and Valeroselect Granted CEP - FoodIngredientsFirst: The company already holds CEPs for naturally sourced Paclitaxel and for Paclitaxel from semisynthesis, as well as for Colchicine. ...
Investigators Eye Oncolytic Virus Therapy | Press Releases @ Your Story: The trial (REO 021) is a single arm, open-label, Phase 2 study of REOLYSIN given intravenously with paclitaxel and carboplatin every three weeks. Up to 55 patients are expected to be treated in this trial. Eligible patients include ...

Do you need an Abraxane lawyer in District of Columbia? Contact one of our Abraxane lawyers in District of Columbia now.

Need An Abraxane Attorney?

First Name Last Name Email Address State

Legal Issue

FDA Drug Database: Abraxane Click to select a Legal Issue

Has Your Health Been Negatively Affected?

Please Describe the Injury

close this window

Abraxane Information

Click to View Our Legal Resources

Do you need an Abraxane lawyer in District of Columbia? Contact one of our Abraxane lawyers in District of Columbia now.

LegalView.info is sponsored by law firms with offices in many states. This website contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Your access to this site does not constitute a legal attorney-client relationship. The choice of a lawyer is an important decision and should not be based solely upon advertisements. To access important information concerning the sponsors and their commitment to the ethical practice of law, click here.

The participating law firms are as follows: Anapol Schwartz (Philadelphia, Pennsylvania; Cherry Hill, New Jersey; Media, Pennsylvania; Reading, Pennsylvania; Wheeling, WV). Cohen, Placitella & Roth (Red Bank, New Jersey; Philadelphia, Pennsylvania). J. F. Humphreys (Charleston, West Virginia). Lopez McHugh (Newport Beach, California; Philadelphia, PA; and Moorestown, NJ). Click here for more information about these law firms.

Some of our partner firms do not accept some types of cases. For details on these case exceptions, click here.

20120517-105243

Close (x)

Looking for an Attorney?

Please type your question:

First Name:
Last Name:
E-mail:
Phone Number *
() -

State * Legal Issue *

FDA Drug Database: Abraxane Click to select a Legal Issue

Close (x)

Find Legal Help for Your Abraxane Case - Submit Your Information Below

Do you need legal assistance with your Abraxane case?
LegalView may be able to help.

Submit your information below for a free, no-cost evaluation.

We'll submit your information to one of our partner firms.
LegalView's partners represent clients throughout the United States, for a very wide range of legal issues. Submit your information now, to see if one of LegalView's partners can help!

* Indicates Required Fields

First name *

Last name *

Email Address *

Phone Number *
() -

State *

Legal Issue * FDA Drug Database: Abraxane Change

Was There an Injury?

Please Describe The Injury

Please State Your Question *

DISCLAIMER and STATEMENT OF NON-CONFIDENTIALITY

By submitting this form, you agree that completing the above is not intended to create an attorney-client relationship.

Disclosure

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website, LegalWebMedia.com will submit your information to the law firms that pay for this group advertising and to respond to your requests for information concerning legal services in their assigned local areas. If there is no sponsoring firm in your state, your inquiry will be submitted to one of the sponsoring law firms on a predetermined, rotating basis. If the sponsoring law firm accepts your case, it will associate with licensed attorneys practicing in your state, if required; the sponsoring law firm may also contact other law firms to see if they may be able to assist.

The information provided by the LegalView.com and LegalWebMedia.com websites is for advertising and informational purposes and should not be considered as legal advice from the sponsoring attorneys. The websites contain general information and may not reflect current legal developments, verdicts, or settlements. LegalView.com contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Any person viewing or receiving information from these websites should not act or refrain from acting on the basis of any such information without first seeking appropriate legal advice from an attorney in your area. Legal WebTV Network, LLC expressly disclaims any liability with respect to actions taken or not taken by the recipient based on any or all of the information or contents contained in these websites.

Any information sent to Legal WebTV Network LLC through this website is done using standard Web encryption techology. LegalView.com will exercise all reasonable care, within technological limits, to protect the confidentiality of any information submitted via Internet e-mail or through this website. By accessing this website, you may be seeking an attorney to represent you or legal advice. However, none of the sponsoring attorneys represent you yet.

The choice of a lawyer is an important decision and should not be based solely upon advertisements.

Any transmission of information, whether via Internet e-mail or through the website, is solely for evaluation purposes by the sponsoring law firms and their associates. The transmission of any information to any attorney sponsoring advertising on LegalView.com or LegalWebMedia.com does not create an attorney-client relationship between the sender and any recipient. An attorney-client relationship can only be created by a written, signed-fee agreement entered into with an attorney. The sponsoring attorneys will treat your information as a confidential communication for the purpose of obtaining legal services or legal advice.

For more information about the sponsoring law firms, please click here.

This form is secure and encrypted. More information about secure forms and your privacy here.